SFB 1243 Cancer Evolution

Breadcrumb Navigation


Recommended Reading

Books – Fiction and Non-Fiction

The Emperor of all Maladies: A Biography of Cancer. by Siddhartha Mukherjee. Simon + Schuster Inc. (2011) ISBN-10: 1439170916, ISBN-13: 9781439170915.
Available on campus for loan in the BMC/Biocenter Biology & Biomedicine Library. (Signature: XH 1500 M953)

Natural Obsessions: The Search for the Oncogene. by Natalie Angier. Orion Hardbacks (1988) ISBN-10: 0395453704, ISBN-13: 978-0395453704.

The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer is Winnable – and How We Can Get There. by Vincent T. DeVita and Elizabeth DeVita-Raeburn. Sarah Crichton Books/Farrar, Straus and Giroux, New York (2015). ISBN-13: 978-0374135607, ISBN-10: 0374135606
Available on campus for loan in the BMC/Biocenter Biology & Biomedicine Library. (Signature: XH 4000 D496)

The Lock and Key of Medicine: Monoclonal Antibodies and the Transformation of Health Care. by Lara V. Marks. Yale University Press (2015) ISBN-10: 0300167733, ISBN-13: 978-0300167733.
Available as ebook through the Universitätsbiobliothek and for loan through the BMC/Biocenter Biology & Biomedicine Library.(Signature: WF 9900 M346)

The End of the Beginning: Cancer, Immunity, and the Future of a Cure. by Michael Kinch. Pegasus Books (2019) ISBN-10: 1643130250, ISBN-13: 978-1643130255.
Available on campus for loan in the BMC/Biocenter Biology & Biomedicine Library. (Signature: XH 3100 K51)

Reviews and Journal Articles:

nature.com Cancer Evolution Collection (selected articles from 2016) http://www.nature.com/collections/yhyydzgkfk/ 

Miller, DR (July 2006), "A tribute to Sidney Farber – the father of modern chemotherapy", British Journal of Haematology, 134 (1): 20–26, doi:10.1111/j.1365-2141.2006.06119.x, PMID 16803563

Richardson, Graham M., Lannigan, Joanne, Macara, Ian G. (2015) Does FACS Perturb Gene Expression? Journal of the International Society for Advancment of Cytometry Part A 87A: 166-175. DOI: 10.1002/cyto.a.22608


Must reads!

(September 2018)

Kridel et al., 2016. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med. Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec. PMID: 27959929 (OW)

Horton et al., 2018. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21. PMID: 28825697 (OW)

Abelson, S. et al., 2018. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 559(7714), pp.400–404. DOI: 10.1038/s41586-018-0317-6
(the publication of the data Liran Shlush showed at our SFB meeting. KM + KS)

Lee, S-H et al., 2018. Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. Nature 2018, 561:127, DOI: 10.1038/s41586-018-0465-8
(because it reports on a novel – and, so far, potentially overlooked – mechanism of tumor suppressor gene inactivation that we may study in our own data sets. KM)

Lee-Six, H. et al., 2018. Population dynamics of normal human blood inferred from somatic mutations. Nature, ePub, DOI 10.1038/s41586-018-0497-0 (KM)

Zambetti NA, et al., 2016. Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia. Cell Stem Cell. 2016 Nov 3;19(5):613-627. doi: 10.1016/j.stem.2016.08.021. Epub 2016 Sep 22. (RO)

Passaro D et al., 2017. Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell. 2017 Sep 11;32(3):324-341.e6. doi: 10.1016/j.ccell.2017.08.001. Epub 2017 Sep 1. (RO)

McKeown M et al. 2017Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα AgonistCancer Discov 7(10); 1136–53. DOI: 10.1158/2159-8290  (GS)

Li S, Mason CE, Melnick A, 2016Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics & Development (36) 100-106. https://doi.org/10.1016/j.gde.2016.03.011. (GS)

Sellar RS, Jaiswal S and Ebert BL, 2018. Predicting progression to AML. Nature Medicine (24) 899-907. https://doi.org/10.1038/s41591-018-0114-7. (KS)

Desai P et al. 2018. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Medicine (24) 1015-1023. https://doi.org/10.1038/s41591-018-0081-z. (KS)

Vu LP and Kharas MG, 2018. Targeting the Residual Leukemia Cells after Chemotherapy. Cancer Cell (34) 353-355. https://doi.org/10.1016/j.ccell.2018.08.012. (KS)

Boyd AL et al., 2018. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell (34:3) 483-498. https://doi.org/10.1016/j.ccell.2018.08.007 (KS + WE)

Pellegrino et al., 2018. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Research (28) 1345-1352. http://dx.doi.org/10.1101/gr.232272.117 (IH)

Li Q et al., 2013. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature (504)143-147. http://dx.doi.org/10.1038/nature12830.
(This is a bit older, but might be of interest with respect to our AML long term treatment experiment. IH)

La Manno G et al., 2018. RNA velocity of single cells. Nature (560) 494-498. https://doi.org/10.1038/s41586-018-0414-6. (Letter, CF)

Chan FC et al., 2018. Novel insights into the diesease dynamics of B-cell lymphomas in the Genomics Era. J Pathol (244) 598-609. DOI: 10.1002/path.5043 (Invited Review, UZ-S)

Rossie D et al., 2017. Diffuse large B-cell lymphoma genotyping on the liquid biopsyBlood (129:14) 1947-1957. DOI 10.1182/blood-2016-05-719641. (UZ-S)

Martincorena I et al., 2017. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell (171:5) 1029-41. e21. http://dx.doi.org/10.1016/j.cell.2017.09.042. (WE)

Quek L et al. 2018. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. (24:8) 1167-1177. doi: 10.1038/s41591-018-0115-6. (PG)

Intlekofer AM et al. 2018. Acquired resistance to IDH inhibition through trans or cis dimer-interface
mutations. Nature. (559:7712)125-129. doi: 10.1038/s41586-018-0251-7. (PG)

Pronier et al. 2018. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood (132:12) 1265-1278. doi:10.1182/blood-2018-03-837468. (PG)

Wei SC, Duffy CR, Allison JP 2018. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov (8:9) 1069-86. DOI: 10.1158/2159-8290.CD-18-0367
(Review. Co-authored by one of this year's Nobel Prize winner, James P. Allison. MS)

June CH and Sadelain M 2018. Chimeric Antigen Receptor Therapy. N Engl J Med (379) 64-73. DOI: 10.1056/NEJMra1706169. (Review. MS)

Le DT et al., 2017. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (357: 6349) 409-413. DOI: 10.1126/science.aan6733. (KPH)

Miao D et al., 2018. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (359: 6377) 801-806. DOI: 10.1126/science.aan5951. (KPH)